Market Overview

Sunovion Announces Positive Top-Line Results from Pivotal Study Evaluating Dasotraline in Adults with Binge Eating Disorder

Share:

– Study met its primary endpoint demonstrating fewer binge days per
week with dasotraline versus placebo in the treatment of adults with
moderate to severe binge eating disorder –

Sunovion
Pharmaceuticals Inc.
(Sunovion) today announced that a study (SEP360-321)
evaluating the efficacy and safety of dasotraline in adults (18 to 55
years of age) with moderate to severe binge eating disorder (BED) met
its primary endpoint, demonstrating a statistically significant decrease
in number of binge days per week (defined as days per week during which
at least one binge episode occurs) from baseline to Week 12 in the group
treated with dasotraline 6 mg/day versus the placebo-treated group. The
study did not meet its primary endpoint for the group treated with
dasotraline 4 mg/day. For both dasotraline dose groups, statistically
significant improvement was demonstrated compared to placebo treatment
in the Binge Eating Clinical Global Impression-Severity (BE-CGI-S) score
and the Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating
(Y-BOCS-BE) total score (these results reflect secondary efficacy
analyses without control for multiplicity).

"Binge eating disorder is associated with significant challenges for
patients, ranging from marked distress and depression, to chronic health
issues including heart disease and type 2 diabetes," said Susan L.
McElroy, M.D., Chief Research Officer at Lindner Center of HOPE,
Professor of Psychiatry and Behavioral Neuroscience at the University of
Cincinnati College of Medicine. "These study results suggest that
dasotraline may be an important new treatment option for adults with
BED, which is encouraging news and provides hope for patients with this
difficult disorder."

Dasotraline, a novel dual-acting dopamine and norepinephrine reuptake
inhibitor (DNRI), was generally well tolerated in both dose groups. The
rate of study discontinuation due to adverse events in the dasotraline 4
mg/day, 6 mg/day and placebo-treatment groups was 8.6 percent, 14.1
percent and 1.2 percent, respectively. The most common (≥10 percent)
adverse events in either dasotraline dose group were insomnia, dry
mouth, headache, decreased appetite, nausea and anxiety, consistent with
previous dasotraline studies.

In the previous pivotal study (SEP360-221),
flexibly dosed dasotraline 4-8 mg/day demonstrated statistically
significant improvement at the 12-week primary endpoint on the change
from baseline in number of binge days per week compared to the
placebo-treated group. Additionally, dasotraline was associated with
statistically significant improvement in the BE-CGI-S score, the
Y-BOCS-BE total score and the percent of subjects with four-week
cessation from binge eating.1 Sunovion announced top-line
results from study SEP360-221 on January 13, 2017
and additional
results on May 23, 2017
at the American Psychiatric Association
Meeting.

"While binge eating disorder is the most common eating disorder in the
U.S., few approved treatment options are available," said Antony Loebel,
M.D., Executive Vice President and Chief Medical Officer at Sunovion,
Head of Global Clinical Development for Sumitomo Dainippon Pharma Group.
"We're encouraged by the positive top-line results of flexible-dose
study SEP360-221, and now fixed-dose study SEP360-321, which taken
together suggest that dasotraline may provide an important new treatment
option for people with binge eating disorder."

Following completion of study SEP360-321, patients had the option to
enroll in a currently ongoing 12-month, open-label extension study (SEP360-322),
evaluating the long-term safety and tolerability of dasotraline in the
treatment of BED.

BED is characterized by recurrent episodes of binge eating that occur at
least once per week for three months and was officially recognized by
the American Psychiatric Association in the Diagnostic and Statistical
Manual of Mental Disorders (DSM), Fifth Edition, in 2013. 2,3

Data from SEP360-321 and SEP 360-221 will support submission of a
marketing application for dasotraline to treat moderate to severe binge
eating disorder in adults in the U.S. in FY2018. Full results are being
analyzed and will be presented at a future scientific congress.

In August 2017, Sunovion submitted a New Drug Application (NDA) for
dasotraline for the treatment of attention deficit hyperactivity
disorder (ADHD) in children, adolescents and adults. In November 2017,
the U.S. Food and Drug Administration (FDA) accepted the NDA for review,
with a PDUFA date set for August 30, 2018.

About Study SEP360-321

SEP360-321 was a Phase 3, 12-week, randomized, double-blind,
parallel-group, multi-center, placebo-controlled, fixed-dose study
comparing dasotraline versus placebo in adults 18 to 55 years of age
with moderate to severe BED. Subjects were randomized to receive fixed,
once-daily doses of dasotraline 4 mg, dasotraline 6 mg or placebo. The
primary efficacy endpoint was the change from baseline in number of
binge days (defined as days during which at least one binge episode
occurred) per week at Week 12. Key secondary endpoints included change
from baseline in the Binge Eating Clinical Global Impression-Severity
(BE-CGI-S) score at Week 12, change from baseline in the Yale-Brown
Obsessive Compulsive Scale Modified for Binge Eating (Y-BOCS-BE) total
score at Week 12, and percent of subjects with a four-week cessation in
binge eating prior to Week 12 or the end of study visit. Based on the
pre-specified statistical analysis plan, these efficacy endpoints could
be tested with control for multiplicity if the primary endpoint for both
dose groups were met.

About Dasotraline

Dasotraline is a new chemical entity that acts as a dual dopamine and
norepinephrine reuptake inhibitor (DNRI). It has an extended half-life
(47-77 hours) that supports the potential for stable plasma
concentrations yielding a continuous therapeutic effect over the 24-hour
dosing interval.

Dasotraline was discovered by Sunovion Pharmaceuticals Inc. and is
currently in development to evaluate its use in treating attention
deficit hyperactivity disorder (ADHD) and binge eating disorder (BED).
It has not been approved by the U.S. Food and Drug Administration (FDA)
for the treatment of ADHD or BED.

About Binge Eating Disorder (BED)

BED is characterized by recurrent episodes of binge eating that occur at
least once per week for three months. An episode of binge eating is
defined as eating an abnormally large amount of food in a discrete
period of time. This is typically accompanied by a sense of lack of
control. Binge eating must be characterized by marked distress and at
least three of the following: eating more rapidly than normal; eating
until feeling uncomfortably full; eating large amounts of food when not
feeling physically hungry; eating alone because of embarrassment and
feeling disgusted, guilty or depressed afterwards.2 The
lifetime prevalence of BED among adult women and men in the U.S. is 3.6
percent and 2.1 percent, respectively.4,5

BED typically begins in adolescence or young adulthood but can also
start later.6 BED can lead to a number of psychological and
physical problems, such as social isolation, feeling bad about oneself,
problems functioning at work, and related medical conditions (e.g.,
gastroesophageal reflux disease, joint problems, heart disease, type 2
diabetes and some sleep-related breathing disorders).7 It is
also associated with increased healthcare utilization, medical morbidity
and mortality.2

About Sunovion Pharmaceuticals Inc. (Sunovion)

Sunovion is a global biopharmaceutical company focused on the innovative
application of science and medicine to help people with serious medical
conditions. Sunovion's vision is to lead the way to a healthier world.
The company's spirit of innovation is driven by the conviction that
scientific excellence paired with meaningful advocacy and relevant
education can improve lives. With patients at the center of everything
it does, Sunovion has charted new paths to life-transforming treatments
that reflect ongoing investments in research and development and an
unwavering commitment to support people with psychiatric, neurological
and respiratory conditions.

Headquartered in Marlborough, Mass., Sunovion is an indirect,
wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., Sunovion
Pharmaceuticals Europe Ltd., based in London, England, and Sunovion
Pharmaceuticals Canada Inc., based in Mississauga, Ontario, are
wholly-owned direct subsidiaries of Sunovion Pharmaceuticals Inc.
Additional information can be found on the company's websites: www.sunovion.com,
www.sunovion.eu and www.sunovion.ca.
Connect with Sunovion on TwitterLinkedInFacebook and YouTube.

About Sumitomo Dainippon Pharma Co., Ltd.

Sumitomo Dainippon Pharma is among the top-ten listed pharmaceutical
companies in Japan, operating globally in major pharmaceutical markets,
including Japan, the U.S., China and the European Union. Sumitomo
Dainippon Pharma aims to create innovative pharmaceutical products in
the Psychiatry & Neurology area, the Oncology area and Regenerative
medicine/Cell therapy field, which have been designated as the focus
therapeutic areas. Sumitomo Dainippon Pharma is based on the merger in
2005 between Dainippon Pharmaceutical Co., Ltd., and Sumitomo
Pharmaceuticals Co., Ltd. Today, Sumitomo Dainippon Pharma has more than
6,000 employees worldwide. Additional information about Sumitomo
Dainippon Pharma is available through its corporate website at www.ds-pharma.com.

SUNOVION is a registered trademark of Sumitomo Dainippon Pharma Co., Ltd.

Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Sumitomo Dainippon
Pharma Co., Ltd.
© 2018 Sunovion Pharmaceuticals Inc.
All rights reserved.

For a copy of this release, visit Sunovion's web site at www.sunovion.com

References

1 B Navia, JI Hudson, SL McElroy, et. al. Dasotraline for the
treatment of moderate to severe binge eating disorder in adults: results
from a randomized, double-blind, placebo-controlled study. Poster #215.
Presented at 30th Annual Psych Congress. September 17-18,
2017.
2 American Psychiatric Association. Diagnostic and
Statistical Manual of Mental Disorders. Fifth Edition. Washington, DC:
American Psychiatric Association, 2013.
3 American
Psychiatric Association. Feeding and Eating Disorders. 2013 [Internet]
Available from: https://www.psychiatry.org/psychiatrists/practice/dsm/educational-resources/dsm-5-fact-sheets
4
Hudson, JI, Hiripi, E, Pope, HG, & Kessler, RC. (2007). The Prevalence
and Correlates of Eating Disorders in the National Comorbidity Survey
Replication. Biological Psychiatry. 61(3), 348–58.
5
Smink, FRE, van Hoeken, D, & Hoek, HW. Epidemiology of Eating Disorders:
Incidence, Prevalence and Mortality Rates. Current Psychiatry Reports.
2012; 14(4), 406–14.
6 American Psychiatric Association.
Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition.
Washington, DC: American Psychiatric Association, 1994.
7
Mayo Clinic. Binge-Eating Disorder: Symptoms and causes. [Internet].
Available from: http://www.mayoclinic.org/diseases-conditions/binge-eating-disorder/basics/complications/con-20033155.
Accessed March 2017
.

View Comments and Join the Discussion!